Funded Startups in San Clemente
Across the 9 most recent funded entries in San Clemente, the largest disclosed round is Osteal Therapeutics’ $16M (2025-11-03).
Across the 9 most recent funded entries in San Clemente, the largest disclosed round is Osteal Therapeutics’ $16M (2025-11-03). That $16M figure is substantially above most other disclosed amounts in the list, with several rounds clustered far lower: Low Rate Co. at $790K (2025-11-21) and The Marygold Companies at $4M (2024-09-24), while the next-highest disclosed amounts are $30M (Project 7, 2025-06-04) and $28M (AtaCor Medical, 2024-04-24).
The list also shows a temporal cluster in 2024: atVenu ($130M on 2024-10-08), The Marygold Companies ($4M on 2024-09-24), and Epica International ($14M on 2024-09-17) are all within about three weeks, alongside AtaCor Medical ($28M on 2024-04-24) and atVenu’s earlier fall date. Sector-wise, the set is concentrated in healthcare-adjacent categories: Biotechnology (Osteal Therapeutics, $16M on 2025-11-03), Health Care (AtaCor Medical, $28M on 2024-04-24), and osteal-related therapeutics appear alongside other non-health themes. Rounds span 2021-05-19 (Sambazon, $45M) through the latest 2025-11-21 (Low Rate Co., $790K), and 5 of 9 entries are labeled “Series Unknown” while 1 is “Undisclosed.”
Most recent rounds
9 shownRelated listings
Frequently asked
Which disclosed round is the standout in San Clemente, and how far above the rest is it?
Osteal Therapeutics’ disclosed $16M round on 2025-11-03 is a clear standout within the disclosed set, but it sits below the highest disclosed amount: Project 7’s $30M on 2025-06-04 and atVenu’s $130M on 2024-10-08 are even larger. The low end is Low Rate Co. at $790K on 2025-11-21.
Do any sectors appear over-represented across these 9 recent entries?
Healthcare-adjacent themes dominate the company mix in practice: Osteal Therapeutics (Biotechnology, $16M on 2025-11-03) and AtaCor Medical (Health Care, $28M on 2024-04-24) account for two distinct healthcare categories. The remaining categories are singletons in this slice, including Real Estate/Finance/FinTech (Low Rate Co., $790K) and Data and Analytics (The Marygold Companies, $4M).
Is there a tight funding window in 2024 where multiple rounds landed close together?
Yes. In September 2024, two consecutive-week entries appear back-to-back: Epica International raised $14M on 2024-09-17, followed by The Marygold Companies at $4M on 2024-09-24. Then atVenu’s $130M closes in late 2024 on 2024-10-08, keeping most of the non-2025 activity within a ~1–2 month stretch of 2024.
What does the stage labeling look like, and does it limit comparability?
Stage information is mostly non-specified: 5 of 9 entries are marked “Series Unknown” (including Project 7 at $30M on 2025-06-04 and Epica International at $14M on 2024-09-17). There is also 1 “Undisclosed” entry (Nomadix, $400K on 2022-04-07) plus one explicit “Series C” (AtaCor Medical, $28M on 2024-04-24), which makes stage-based comparisons difficult across the list.
Are there outliers in size that would skew analysis of ‘typical’ rounds?
atVenu’s $130M on 2024-10-08 is an extreme high relative to most other disclosed amounts shown (for example, The Marygold Companies at $4M on 2024-09-24 and Low Rate Co. at $790K on 2025-11-21). Conversely, Low Rate Co.’s $790K (Seed on 2025-11-21) is a low-end outlier versus the rest of the disclosed figures.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.